

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

NCT07431086

Status	RECRUITING
Phase	Phase 2
Sponsor	Regeneron Pharmaceuticals
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (2)

- Body mass index ≥ 27.0 kg/m² to < 45.0 kg/m² at screening
- Demonstrates ability and willingness to comply with the study protocol, including attending all scheduled visits, adhering to the prescribed treatment regimen, and completing all required assessment

Exclusion (5)

- History of Type 1 or Type 2 diabetes
- Change in body weight > 5 kg within approximately 3 months before screening
- History of gastrointestinal (GI) surgery or procedures for weight management including bariatric surgery or planned bariatric surgery (includes removal or reversal, etc); presence of serious GI disorders (eg, active peptic ulcer, inflammatory bowel disease) and/or history of clinically significant gastric emptying abnormality or on chronic medication that alters GI motility
- Past medical history of moderate to severe depression or history of suicidal behavior, or past medical history of serious psychiatric disorder as described in the protocol
- History of any of the following conditions: acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones or has a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years as described in the protocol

Locations (1 total)

Flourish Research - San Antonio Medical Trials, San Antonio, Texas, United States